Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study assessing ZN-c3 in Combination With Chemotherapy in Patients with Ovarian Cancer

Next Previous
Trial Profile

A Phase III Study assessing ZN-c3 in Combination With Chemotherapy in Patients with Ovarian Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azenosertib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
  • Indications Ovarian cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Zentalis Pharmaceuticals

Most Recent Events

  • 26 Mar 2025 According to Zentalis pharmaceuticals media release, company plans to treat the same patient population (from DENALI part 2 trial) in its Phase 3 randomized confirmatory study, which the company plans to enroll concurrently with Part 2b, subject to FDA feedback.
  • 07 May 2024 According to Zentalis pharmaceuticals media release, the company expect additional details on design of planned registration-enabling trial of azenosertib in PSOC in the 1L maintenance setting in 2H 2024 and initiate this trial in 2025.
  • 25 May 2023 According to Zentalis pharmaceuticals media release, the company expect to initiate this trial in the first quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top